Last update: Aug. 12, 2019

Cinnarizine

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

A calcium channel blocker drug and an antihistamine piperazine derivative which has a sedative effect. Chemical structure and effects similar to Flunarizine.
Used to treat nausea and vertigo of Meniere's Disease, and symptoms of Traveler´s Sickness.
It has been withdrawn from the market in several countries because of Parkinson-like symptoms (Teive 2004, Martí 1985).

At latest update relevant published data were not found on excretion into breast milk.

Its high binding capacity to plasma proteins makes it unlikely excretion into breastmilk.

It should be wise on the long-term, the use of a known safer alternative until more data is available on this drug, mostly for children in the neonatal period or in case of prematurity that may be affected by an increased gut permeability. Occasional use to prevent motion sickness may be compatible with breastfeeding.


See below the information of this related product:

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Cinnarizine in other languages or writings:

Group

Cinnarizine belongs to this group or family:

Tradenames

Main tradenames from several countries containing Cinnarizine in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 369 daltons
Protein Binding 91 %
pKa 8,4 -
Tmax 1 - 3 hours
T1/2 3 - 24 hours

References

  1. Janssen. Cinarizina (Stugeron forte). Ficha técnica 2017 Full text (in our servers)
  2. Teive HA, Troiano AR, Germiniani FM, Werneck LC. Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis. Parkinsonism Relat Disord. 2004 Abstract
  3. Castañeda-Hernández G, Vargas-Alvarado Y, Aguirre F, Flores-Murrieta FJ. Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers. Arzneimittelforschung. 1993 May;43(5):539-42. Abstract
  4. Paton DM, Webster DR. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985 Nov-Dec;10(6):477-97. Review. Abstract
  5. Martí Massó JF, Carrera N, de la Puente E. [Parkinsonism possibly caused by cinnarizine]. Med Clin (Barc). 1985 Abstract

Total visits

17,702

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by AELAMA

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM